Transcatheter aortic valve replacement in patients with a history of cancer: Periprocedural and long-term outcomes
Alexandra C Murphy, Anoop N Koshy, William Cameron, Mark Horrigan, Leighton Kearney, Belinda Yeo, Omar Farouque, Matias B Yudi
Catheterization and Cardiovascular Interventions | WILEY | Published : 2020
BACKGROUND: A history of cancer is incorporated into the surgical risk assessment of patients undergoing surgical aortic valve replacement through the Society for Thoracic Surgeons score. However, the prognostic significance of cancer in patients treated with transcatheter aortic valve replacement (TAVR) is unclear. As the cancer survivorship population increases, it is imperative to establish the efficacy and safety of TAVR in patients with severe symptomatic aortic stenosis (AS) and a history of malignancy. OBJECTIVES: The primary goal of this study was to assess the periprocedural outcomes and long-term mortality in patients with a history of cancer undergoing TAVR. METHODS: A systematic ..View full abstract
Dr Alexandra Murphy is supported by the Cardiac Society of Australia and New Zealand PhD Scholarship.